Quantinno Capital Management LP Increases Stock Position in Insulet Co. (NASDAQ:PODD)

Quantinno Capital Management LP increased its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 104.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,421 shares of the medical instruments supplier's stock after purchasing an additional 14,005 shares during the quarter. Quantinno Capital Management LP's holdings in Insulet were worth $7,159,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of PODD. Horizon Investments LLC increased its position in Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock worth $1,146,000 after purchasing an additional 43 shares during the period. Wilmington Savings Fund Society FSB lifted its position in Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after acquiring an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after acquiring an additional 48 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its position in Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after acquiring an additional 50 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PODD. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target on the stock. Oppenheimer upped their target price on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Barclays increased their price objective on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research report on Friday. Finally, Raymond James reissued an "outperform" rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $306.53.

Insider Buying and Selling

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Insulet Stock Performance

Insulet stock traded up $1.63 during mid-day trading on Tuesday, reaching $327.47. 998,435 shares of the stock traded hands, compared to its average volume of 708,069. The stock has a market capitalization of $23.05 billion, a PE ratio of 56.56, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a 12-month low of $170.67 and a 12-month high of $328.84. The business's 50-day moving average is $265.69 and its 200-day moving average is $267.57.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 EPS. As a group, sell-side analysts predict that Insulet Co. will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.